Physician profile
Jeffrey D Wilharm
NPI 1982605762
$2,332.12
in general payments reported to CMS, 2019-2025
14 companies · $18.00 in 2025
The $18.00 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $601 · 2021: $232 · 2022: $61.26 · 2023: $71.17 · 2024: $144 · 2025: $18.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $651.94 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $397.05 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $217.54 | 2019-2022 | |
| Abbvie INC. | $206.78 | 2021-2023 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $178.57 | 2019-2022 | |
| Lundbeck LLC | $153.84 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $136.14 | 2019-2020 | |
| Alkermes, INC. | $126.83 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.63 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $57.14 | 2019-2020 | |
| Shire North American Group INC | $52.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.16 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $30.51 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wilharm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.